University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

Monte Rosa Therapeutics, a US-based biotechnology developer exploiting Institute of Cancer Research work, picked up $96m in a series B round on Thursday led by Aisling Capital.
GV, an early-stage investment subsidiary of internet technology group Alphabet, Versant Ventures, New Enterprise Associates (NEA), HBM Healthcare Investments, Cormorant Asset Management, Amzak Health, Casdin Capital, Sixty Degree Capital and Cambridge Asset Management also took part.
Monte Rosa Therapeutics is working on precision medicine to degrade proteins causing diseases such as…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in